Evidence map›Paper›PMID 34375445›Full record

SynthesisEuropean journal of clinical investigation2021

CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence.

Chiraphat Kloypan, Matthanaporn Saesong, Juthamat Sangsuemoon, Prawat Chantharit, Pajaree Mongkhon

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Medicina (Kaunas, Lithuania) · 2022
    Review
  16. Review
  17. Article
  18. Correspondence on 'CONVALESCENT plasma for COVID-19'.European journal of clinical investigation · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Chiraphat KloypanDivision of Clinical Immunology and Transfusion Science, Department of Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Thailand.ORCID https://orcid.org/0000-0003-0547-1381
Matthanaporn SaesongDivision of Clinical Immunology and Transfusion Science, Department of Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Thailand.
Juthamat SangsuemoonDivision of Clinical Immunology and Transfusion Science, Department of Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Thailand.
Prawat ChantharitDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-5533-5698
Pajaree MongkhonDivision of Pharmacy Practice, Department of Pharmaceutical Care, Unit of Excellence on Research in Health Outcomes and Patient Safety in Elderly, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.ORCID https://orcid.org/0000-0002-3050-1557

Funding

Thailand Science Research and Innovation Fund and the University of Phayao FF64-UoE039
6 · The paper itself

Abstract

backgroundThere is still a lack of consensus on the efficacy of convalescent plasma (CP) treatment in COVID-19 patients. We performed a systematic review and meta-analysis to investigate the efficacy of CP vs standard treatment/non-CP on clinical outcomes in COVID-19 patients.

methodsCochrane Library, PubMed, EMBASE and ClinicalTrials.gov were searched from December 2019 to 16 July 2021, for data from clinical trials and observational studies. The primary outcome was all-cause mortality. Risk estimates were pooled using a random-effect model. Risk of bias was assessed by Cochrane Risk of Bias tool for clinical trials and Newcastle-Ottawa Scale for observational studies.

resultsIn total, 18 peer-reviewed clinical trials, 3 preprints and 26 observational studies met the inclusion criteria. In the meta-analysis of 18 peer-reviewed trials, CP use had a 31% reduced risk of all-cause mortality compared with standard treatment use (pooled risk ratio [RR] = 0.69, 95% confidence interval [CI]: 0.56-0.86, P = .001, I

conclusionsConvalescent plasma use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients. However, the findings were limited with a moderate degree of heterogeneity. Further studies with well-designed and larger sample size are needed.

Indexed as

MortalityCause of DeathCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveLength of StayRandomized Controlled Trials as TopicSARS-CoV-2Severity of Illness IndexTreatment Outcomeconvalescent plasmaCOVID-19donorsemerging diseasesmeta-analysissevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Identifiers

PMID34375445
PMCPMC8420367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.